{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-24-000036","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.689136+00:00","generated_at":"2026-05-31T11:24:52.194124+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apyx Medical Q2 revenue falls 10% to $12.1M; net loss widens; updates FY2024 guidance","bullets":["Revenue $12.1M (-10% YoY); Advanced Energy -17% to $9.8M, OEM +29% to $2.4M.","Net loss $6.6M ($0.19/share) vs $1.0M loss in Q2 2023; prior year had $2.7M sale-leaseback gain.","Adjusted EBITDA loss $4.3M, up 166% from $1.6M loss in Q2 2023.","FY2024 revenue guidance narrowed to $50.6-52.1M (from $49.7-52.9M); net loss guided $23.5-24.5M (improved).","Stavros Vizirgianakis appointed Chairman effective May 7, 2024, succeeding retiring Andrew Makrides."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-24-000036","json":"https://secwatch.observer/filing/0000719135-24-000036.json","markdown":"https://secwatch.observer/filing/0000719135-24-000036.md","text":"https://secwatch.observer/filing/0000719135-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000036/0000719135-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000036/apyx-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:24:52.194124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}